Libero Pharma
Libero Pharma develops transdermal delivery systems for established opioid receptor antagonists, primarily focusing on Naltrexone, to address high unmet medical needs in chronic conditions including addiction, fibromyalgia, and Crohn’s disease. By employing patient-friendly transdermal patches, the company aims to enable better therapeutic outcomes through sustained drug delivery for individuals where existing oral or injectable treatments offer limited access or efficacy. The company has received notable research support, including a significant grant from the National Institute of Drug Abuse (NIDA), and focuses on expedited regulatory pathways leveraging established safety and efficacy data.
Industries
N/A
Libero Pharma
International House, 38 Thistle Street, Edinburgh, EH2 1EN, Scotland, UK
Patents
Products
A transdermal patch delivering sustained levels of naltrexone to support relapse prevention in opioid use disorder.
A transdermal patch formulation to maintain consistent plasma naltrexone levels for reducing alcohol consumption.
A new transdermal formulation under development to provide symptom relief for fibromyalgia patients where oral options are ineffective or unavailable.
A transdermal naltrexone product being developed to help manage symptoms and reduce complications in Crohn's disease.
A transdermal patch delivering sustained levels of naltrexone to support relapse prevention in opioid use disorder.
A transdermal patch formulation to maintain consistent plasma naltrexone levels for reducing alcohol consumption.
A new transdermal formulation under development to provide symptom relief for fibromyalgia patients where oral options are ineffective or unavailable.
A transdermal naltrexone product being developed to help manage symptoms and reduce complications in Crohn's disease.
Expertise Areas
- Transdermal therapeutics
- Addiction medicine
- Chronic inflammatory disease management
- Psychiatric and central nervous system disorders
Key Technologies
- Transdermal patch technology
- Opioid receptor antagonism
- Formulation science
Key People
News & Updates
Received the largest National Institute of Drug Abuse (NIDA) grant for an ex-US entity in 2022 to develop lead transdermal medicine.
Received the largest National Institute of Drug Abuse (NIDA) grant for an ex-US entity in 2022 to develop lead transdermal medicine.